A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/16/2006	US20060257474 anti-thrombocytic agent and an HMG-CoA reductase inhibitor in an amount sufficient to treat chronic glomerular nephritis wherein the anti-thrombocytic agent is selected from dilazep, dipyridamole and or salts thereof and the HMG-CoA reductase inhibitor is pitavastatin
11/16/2006	US20060257472 Stability of progestogen formulations
11/16/2006	US20060257471 Pharmaceutical tablets of crystalline Type II aripiprazole
11/16/2006	US20060257470 Method for producing solid galenic formulations using a crosslinked non-thermoplastic carrier
11/16/2006	US20060257469 Enhanced indoleamine and catecholamine bio-availability via catechin inhibition of L-Dopa decarboxylase
11/16/2006	US20060257467 Compositions and methods for inhibiting gastric acid secretion
11/16/2006	US20060257466 Administration of macrophage targeted formulations of compounds which modulate cholesterol-metabolizing enzymes for treatment of atherosclerosis
11/16/2006	US20060257463 Transmucosal delivery of cannabinoids
11/16/2006	US20060257459 Carrier
11/16/2006	US20060257454 Conjugated fatty acid esters
11/16/2006	US20060257450 Drug delivery systems for treatment of diseases or conditions
11/16/2006	US20060257436 Skin preparation composition for external use
11/16/2006	US20060257435 Concentrated water-dispersible vitamin compositions
11/16/2006	US20060257433 Formulation
11/16/2006	US20060257432 Pharmaceutical formulations of xanthogenates and inhibitors of viral nucelic acid replication
11/16/2006	US20060257422 cell walls of yeast of the species Saccharomyces cerevisiae, having glucans, mannans, and glycogen; antidiabetic agent; non-insulin dependent diabetes
11/16/2006	US20060257419 Bordetella pertussis antigen consisting lipopolysaccharide, pertusis toxin, filamentous hemagglutinin, pertactin or abosrbed to alum; interleukin-12 ; enhances cell-mediated immunity in a host
11/16/2006	US20060257401 Sensitizing cells for apoptosis by selectively blocking cytokines
11/16/2006	US20060257400 Combination therapy
11/16/2006	US20060257390 Catheter Composition and Uses Thereof
11/16/2006	US20060257388 Drug delivery systems for stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
11/16/2006	US20060257384 Compositions comprising lactobacillus plantarum strains in combination with tannin and new lactobacillus plantarum strains
11/16/2006	US20060257368 Devices and methods for improved viability of cells
11/16/2006	US20060257367 Tumour-cell specific gene expression and its use in cancer therapy
11/16/2006	US20060257365 Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
11/16/2006	US20060257362 Method and composition for preventing and reating solid tumors
11/16/2006	US20060257355 Impregnated polymer compositions and devices using them
11/16/2006	US20060257354 Ethylene copolymer waxes containing amino groups and use thereof
11/16/2006	US20060257351 administering, to a subject a formulation containing2-(3,4-dihydroxyphenyl)ethanol or a glucoside; and cysteine or cystine for potentiating glutathione, for promoting the production of a gamma -glutamylcysteine synthetase, glutathione reductase; antiaging agents, nutraceuticals, sunscreen agents
11/16/2006	US20060257337 Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
11/16/2006	US20060257330 Powdery pharmaceutical compositions for inhalation
11/16/2006	US20060257329 Delivery of drug esters through an inhalation route
11/16/2006	US20060257328 Delivery of caffeine through an inhalation route
11/16/2006	US20060257327 Medical product
11/16/2006	US20060257326 Methods and formulations for delivery of pharmacologically active agents
11/16/2006	US20060257325 Method and Package for Storing a Pressurized Container Containing a Drug
11/16/2006	US20060257324 Pharmaceutical solution formulations for pressurised metered dose inhalers
11/16/2006	US20060257320 Biodegradable polyacetals and methods
11/16/2006	US20060257317 Combination therapy in the treatment of cancer
11/16/2006	US20060257281 Adhesion inhibition of microorganisms by non-ionic surfactants
11/16/2006	US20060255323 Process for producing fine particles of organic compound
11/16/2006	DE202006014258U1 Formulation, useful for skin cream foam, comprises an aqueous emulsion and a carrier gas, where the emulsion contains urea, hyaluronic acid, a free fatty acid and emulsifying agents
11/16/2006	DE19948436B4 Bicyclische Imidazo-5-aminderivate Bicyclic imidazo-5-amine derivatives
11/16/2006	DE102005023301A1 Medicament used to reduce risk of e.g. heart disease and urinary tract disease, comprises 5-methyl-(6S)-tetrahydrofolate, estrogen and/or gestagene, vitamin B6 and/or vitamin B2 and auxiliary or carrier materials
11/16/2006	DE102005022321A1 Composition, useful e.g. as nutritional supplement, comprises vitamin C, vitamin E, coenzyme Q10, carotinoid e.g. beta-carotin, selenium, zinc, and copper, where the components are from natural plant and animal source
11/16/2006	DE102005022290A1 Composition, useful to treat or prevent viral infection, comprises a hexanucleotide as biological component and optionally a carrier, where the hexanucleotide arranged in specific direction against a protein-like biopolymer
11/16/2006	DE102005022276A1 Derivate von Dihydroxyphenylalanin Derivatives of dihydroxyphenylalanine
11/16/2006	DE102005022182A1 Modulatoren der PDZ-Domäne Modulators of the PDZ domain
11/16/2006	DE102005022021A1 Isoalkane mixture, useful in hydrophobic component of homogenous/heterogeneous phase of cosmetic or pharmaceutical composition e.g. skin protectant, decorative cosmetic and hair treatment agent for damp bearing of skin
11/16/2006	DE102005012875B4 Verwendung von Amino substituierten 8-N-Benzimidazolen Use of amino-substituted 8-N-benzimidazoles
11/16/2006	CA2651376A1 Method for diagnosis and treatment of a mental disease
11/16/2006	CA2614192A1 Use of docosahexaenoic glycerides for the treatment of tumoral diseases
11/16/2006	CA2609296A1 Nanoparticulate and controlled release compositions comprising a cephalosporin
11/16/2006	CA2608889A1 Dibenzocycloheptane compounds and pharmaceuticals containing these compounds
11/16/2006	CA2608643A1 Gene-based algorithmic cancer prognosis
11/16/2006	CA2608326A1 Pteridines useful as hcv inhibitors and methods for the preparation thereof
11/16/2006	CA2608301A1 Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof
11/16/2006	CA2608249A1 Method for the treatment of drug abuse with flibanserin
11/16/2006	CA2608248A1 Soluble epoxide hydrolase inhibitors and methods of using same
11/16/2006	CA2608243A1 Acyl hydrazones for treating cardiovascular diseases
11/16/2006	CA2608194A1 Compounds for modulating trpv3 function
11/16/2006	CA2608184A1 N,n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
11/16/2006	CA2608120A1 Pharmaceutical composition for the inhibition of lipogenesis comprising a regulator of prp19 expression
11/16/2006	CA2608116A1 Method of modulating stress-activated protein kinase system
11/16/2006	CA2608108A1 Organometal benzenephosphonate coupling agents
11/16/2006	CA2608091A1 Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
11/16/2006	CA2608061A1 Pharmaceutical composition including an anti-tumoral and an active ingredient selected among carveol, thymol, eugenol, borneol and carvacrol
11/16/2006	CA2608060A1 Composition for treatment or prevention of problems relating to a disturbance of the biological clock
11/16/2006	CA2608052A1 Novel use of liver x receptor agonists
11/16/2006	CA2608024A1 Use of flibanserin in the treatment of chronic pain
11/16/2006	CA2608023A1 Compositions comprising calcipotriol and nicotinamide for treating hyperproliferative epidermal diseases
11/16/2006	CA2607988A1 Method for the resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazol and intermediate compounds
11/16/2006	CA2607953A1 Methods for treating nephrolithiasis
11/16/2006	CA2607938A1 Benzoic acid derivatives that are modulators or agonists of glyr
11/16/2006	CA2607934A1 Method for preparation of optionally 2-substituted 1,6-dihydro-6-oxo-4-pyrimidinecarboxylic acids
11/16/2006	CA2607933A1 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones which modulate the function of the vanilloid-1 receptor (vr1)
11/16/2006	CA2607929A1 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)
11/16/2006	CA2607912A1 Medical composition for promotion of skin regeneration
11/16/2006	CA2607803A1 Compositions and methods for inhibiting gastric acid secretion
11/16/2006	CA2607802A1 Pharmaceutical formulation of apomorphine for buccal administration
11/16/2006	CA2607670A1 Bicyclic derivatives as modulators of ion channels
11/16/2006	CA2607660A1 N-thiolated 2-oxazolidone antibiotics
11/16/2006	CA2607639A1 Crystal of indole derivative having piperidine ring and process for production thereof
11/16/2006	CA2607626A1 Modified release famciclovir pharmaceutical compositions
11/16/2006	CA2607624A1 Extrusion process for making compositions with poorly compressible therapeutic compounds
11/16/2006	CA2607617A1 Thiazole compounds and methods of use
11/16/2006	CA2607608A1 Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
11/16/2006	CA2607561A1 Pharmaceutical composition
11/16/2006	CA2607496A1 Production of glucosamine from plant species
11/16/2006	CA2607486A1 Production of glucosamine from plant species
11/16/2006	CA2607427A1 Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
11/16/2006	CA2607421A1 Thienopyrroles as antiviral agents
11/16/2006	CA2607336A1 Therapeutic sclerosing foam made preferably xenon
11/16/2006	CA2607331A1 Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative
11/16/2006	CA2607267A1 Health food and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage
11/16/2006	CA2607260A1 Compositions and methods for treatment for neoplasms
11/16/2006	CA2607257A1 Unsolvated and host-guest solvated crystalline forms of (2e,4s)-4-[(n-{[(2r)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-l-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses
11/16/2006	CA2607198A1 Dihydroxyphenylalanine derivatives
11/16/2006	CA2607143A1 Delivery of tigecycline in the presence of heparin
11/16/2006	CA2607121A1 Diacylglycerol acyltransferase inhibitors

1 ... 4006 4007 4008 4009 4010 4011 4012 4013 4014 4015 4016 4017 4018 4019 4020 4021 4022 4023 4024 4025 4026 ... 7860